Genzyme releases two molecular tests for acute myelogenous leukemia

By Elaine Rigoli

Tampa, Fla., May 17 - Genzyme Corp. announced the availability of two new molecular tests for acute myelogenous leukemia with the launch of FLT3 mutation analysis and WT1 RQ-PCR.

FLT3 mutations are considered a prognostic indicator of poor survival and response to standard chemotherapies.

The WT1 RQ PCR test allows physicians to monitor acute myelogenous leukemia patients for early relapse during and following therapy. Together, these tests may enable oncologists to better manage their patients, the company said in a news release.

FLT3 receptor mutations are one of the most common genetic abnormalities in acute myelogenous leukemia and have been shown to be an independent predictor of survival, the release said.

About 30% of patients with acute myelogenous leukemia have FLT3 mutations.

Genzyme's WT1 RQ-PCR test is designed to detect minimal residual disease, or very low levels of disease. The WT1 gene is expressed in about 90% of patients with acute myelogenous leukemia, the release said.

Genzyme is a biotechnology company located in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.